A vasoactive intestinal peptide receptor analog alters the expression of homeobox genes

Life Sciences

Volumn 71, Issue 21, 2002, Pages 2543-2552

  Steingart, Ruth A ^a   Heldenberg, Eitan ^a   Pinhasov, Albert ^a   Brenneman, Douglas E ^b   Fridkin, Mati ^c   Gozes, Illana ^a  

^a TEL AVIV UNIVERSITY   (Israel)

^b EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

^c WEIZMANN INSTITUTE OF SCIENCE   (Israel)

Author keywords

Homeobox genes; HT 29 cell line; Stearyl Nle17 neurotensin6 11VIP7 28 (SNH); Vasoactive intestinal peptide (VIP)

Indexed keywords

ANTINEOPLASTIC AGENT; HOMEODOMAIN PROTEIN; OCTAMER TRANSCRIPTION FACTOR 4; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG; VASOACTIVE INTESTINAL POLYPEPTIDE RECEPTOR; VASOACTIVE INTESTINAL POLYPEPTIDE[7-28]NEUROTENSIN[6-11][STEARYL 17 NORLEUCINE];

ARTICLE; CELL STRAIN HT29; CONTROLLED STUDY; DNA BINDING MOTIF; DNA SEQUENCE; GENE EXPRESSION REGULATION; GENETIC CODE; HOMEOBOX; HUMAN; HUMAN CELL; MULTIGENE FAMILY; NUCLEOTIDE SEQUENCE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

DNA PRIMERS; DNA-BINDING PROTEINS; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, HOMEOBOX; HOMEODOMAIN PROTEINS; HT29 CELLS; HUMANS; NEUROTENSIN; OCTAMER TRANSCRIPTION FACTOR-3; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, NEOPLASM; TRANSCRIPTION FACTORS; VASOACTIVE INTESTINAL PEPTIDE;

EID: 0037063712     PISSN: 00243205     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0024-3205(02)02082-9     Document Type: Article

References (43)

1. Gozes I., Meltzer E., Rubinrout S., Brenneman D.E., Fridkin M. Vasoactive intestinal peptide potentiates sexual behavior: inhibition by novel antagonist. Endocrinolgy. 125:1989;2945-2949.
2. Gozes I., McCune S.K., Jacobson I., Warren D., Moody T.W., Fridkin M., Brenneman D.E. An antagonist to vasoactive intestinal peptide affect cellular functions in the central nervous system. Journal of Pharmacology and Experimental Therapeutics. 257:1991;959-966.
3. Gressens P., Hill J.M., Gozes I., Fridkin M., Brenneman D.E. Growth factor function of vasoactive intestinal peptide in whole cultured mouse embryos. Nature. 362:1993;155-158.
4. Gozes I., Shani Y., Rostene W.H. Developmental expression of the VIP-gene in brain and intestine. Brain Research. 388:1987;137-148.
5. Wollman Y., Lilling G., Goldstein M.N., Fridkin M., Gozes I. Vasoactive intestinal peptide: a growth promoter in neuroblastoma cells. Brain Research. 624:1993;339-341.
6. Delgado M., Martinez C., Leceta J., Gomariz R.P. Vasoactive intestinal peptide in thymus: synthesis, receptors and biological actions. Neuroimmunomodulation. 6(1-2):1999;97-107.
7. Gozes I., Fridkin M., Hill J.M., Brenneman D.E. Pharmaceutical VIP: prospects and problems. Current Medicinal Chemistry. 1999;1019-1034.
8. Gelber E., Granoth R., Fridkin M., Dreznik Z., Brenneman D.E., Moody W.T., Gozes I. A lipophilic vasoactive intestinal peptide analog enhances the antiproliferative effect of chemotherapeutic agents of cancer cell lines. Cancer. 92(8):2001;1-9.
9. Moody T.W., Zia F., Draoui M., Brenneman D.E., Fridkin M., Davidson A., Gozes I. A novel VIP antagonist inhibits non-small cell lung cancer growth. Proceedings of the National Academy of Sciences USA. 90:1993;4345-4349.
10. Lilling G., Wollman Y., Goldstein M.N., Rubinraut S., Fridkin M., Brenneman D.E. Inhibition of human neuroblastoma growth by a specific VIP antagonist. Journal of Molecular Neuroscience. 5:1995;231-239.
11. Zia H., Hida T., Jakowlew S., Birrer M., Gozes Y., Reubi J.C., Fridkin M., Gozes I., Moody T.W. Breast cancer growth is inhibited by vasoactive intestinal peptide (VIP) hybrid, a synthetic VIP receptor antagonist. Cancer Research. 56:1996;3486-3489.
12. Gozes I., Nesher Y., Lilling G., Fridkin M., Rubinraut S., Brenneman D.E., Moody T.W. Inhibition of colon cancer by VIP antagonist through a cancer-associated VIP-receptor. Proceedings of the 15th World Congress of Collegium Internationale Chirugiae. 1996;819-821.
13. Sharma A., Walters J., Gozes Y., Fridkin M., Brenneman D.E., Gozes I., Moody T.W. A vasoactive intestinal peptide antagonist inhibits the growth of glooblastoma cells. Journal of Molecular Neuroscience. 17:2001;71-79.
14. Gozes I., Lilling G., Glazer R., Ticher A., Ashkenazi I.E., Davidson A., Rubinraut S., Fridkin M., Brenneman D.E. Superactive lipophilic peptides discriminate multiple VIP receptors. Journal of Pharmacology and Experimental Therapeutics. 273:1995;161-167.
15. Moody T.W., Jensen R.T., Fridkin M., Gozes I. (N-Stearyl, Norleucine 17) VIP hybrid is a broad-spectrum vasoactive intestinal peptide receptor antagonist. Journal of Molecular Neuroscience. 18:2002;29-35.
16. Zia H., Leyton J., Casibang M., Hau V., Brenneman D.E., Fridkin M., Gozes I., Moody T.W. (N-stearyl, norleucine17) VIP hybrid inhibits the growth of pancreatic cancer cell lines. Life Sciences. 66:2000;379-387.
17. Moody T.W., Leyton J., Coelho T., Jakowlew S., Takahashi K., Jameison F., Koh M., Fridkin M., Gozes I., Knight M. (Stearyl, Norleucine17)VIP hybrid antagonizes VIP receptors on non-small cell lung cancer cells. Life Sciences. 61:1997;1657-1666.
18. Granoth R., Fridkin M., Rubinraut S., Gozes I. VIP-derived sequences modified by N-terminal stearyl moiety induce cell death: the human keratinocyte as a model. FEBS Letters. 475:2000;71-77.
19. Moody T.W., Leyton J., Chan D., Brenneman D.C., Fridkin M., Gelber E., Levy A., Gozes I. VIP receptor antagonists and chemotherapeutic drugs inhibit the growth of breast cancer cells. Breast Cancer Research and Treatment. 68:2001;55-64.
20. Gehring W.J., Affolter M., Burglin T. Homeodomain proteins. Annual Review of Biochemistry. 63:1994;487-526.
21. Cillo C., Faucella A., Cantule M., Boncinelli E. Homeobox genes and cancer. Experimental Cell Research. 248:1999;1-9.
22. Cillo C., Cantile M., Faiella A., Boncinelli E. Homeobox genes in normal and malignant cells. Journal of Cellular Physiology. 188(2):2001;161-169.
23. Vider B.Z., Zimber A., Chastre E., Gespach C., Halperin M., Mashiah P., Yaniv A. Deregulated expression of homeobox-containing gene, HOX B6, B8, C9, and Cxd-1 in human colon. Biochemical and Biophysical Research Communications. 272:2000;513-518.
24. Veenstra G.J., van der Vliet P.C., Destree O.H. POU domain transcription factors in embryonic development. Molecular Biology Reports. 24:1997;139-155.
25. Andersen B., Rosenfeld M.G. POU domain factors in the neuroendocrine system: lessons from developmental biology provide insights into human disease. Endocrinology Review. 22:2001;2-35.
26. Eisen T., Easty D.J., Bennett D.C., Goding C.R. The POU domain transcription factor Brn-2: elevated expression in malignant melanoma and regulation of melanocyte-specific gene expression. Oncogene. 11:1995;2157-2164.
27. Jin T., Branch D.R., Zhang X., Qi S., Youngson B., Goss P.E. Examination of POU homeobox gene expression in human breast cancer cells. International Journal of Cancer. 81:1999;104-112.
28. Harmar A.J., Arimura A., Gozes I., Journot L., Laburthe M., Pisegna J.R., Rawlings S.R., Robberecht P., Said S.I., Sreedharan S.P., Wank S.A., Waschek J.A. International Union of Pharmacology XVIII. Nomenclature of receptors for vasoactive intestinal peptide (VIP) and Pituitary Adenylate Cyclase Activating Polypeptide (PACAP). Pharmacology Review. 50:1998;265-270.
29. Reubi J.C. In vitro identification of vasoactive intestinal peptide receptors in human tumors: implications for tumor imaging. Journal of Nuclear Medicine. 36:1995;1846-1853.
30. Luis J., Muller J.M., Abadie B., Martin J.M., Marvaldi J., Pichon J. Cycle of the vasoactive intestinal peptide and its binding site in a human adenocarcinoma cell line (HT 29). European Journal of Biochemistry. 156:1986;631-636.
31. Marchis-Mouren G., Martin J.M., Luis J., el Battari A., Muller J.M., Marvaldi J., Pichon J. HT 29, a model cell line stimulation by the vasoactive intestinal peptide (VIP); VIP receptor structure and metabolism. Biochimie. 70:1988;663-671.
32. Pichon J., Hirn M., Muller J.M., Mangeat P., Marvaldi J. Anti-cell surface monoclonal antibodies which antagonize the action of VIP in a human adenocarcinoma cell line (HT 29 cells). EMBO Journal. 2:1983;1017-1022.
33. Sreedharan S.P., Huang J.X., Cheung M.C., Goetzl E.J. Structure, expression, and chromosomal localization of the type I human vasoactive intestinal peptide receptor gene. Proceeding of the National Academy of Science USA. 92:1995;2939-2943.
34. Reubi J.C., Laderach U., Waser B., Gebbers J.O., Robberecht P., Laissue J.A. Vasoactive intestinal peptide/pituitary adenylate cyclase-activating peptide receptor subtype in human tumors and their tissues of origin. Cancer Research. 60:2000;3105-3112.
35. Moody T.W., Walters J., Casibang M., Zia F., Gozes Y. VPAC1 receptors and lung cancer. Annals of the NY Academy of Science. 921:2000;26-32.
36. Dager S., Sekosan M., Rubinstein I., Onyuksel H. Detection of VIP receptors in MNU- induced breast cancer in rats: implication for breast cancer target. Breast Cancer Research and Treatment. 65:2001;49-54.
37. Boncinelli E., Simeone A., Acampora D., Mavilio F. HOX gene activation by retinoic acid. Trends in Genetics. 7:1991;329-334.
38. Doerksen L.F., Bhattacharya A., Kannan P., Pratt D., Tainsky M.A. Functional interaction between RARE and an AP-2 binding site in the regulation of the human HOX A4 gene promotor. Nucleic Acid Research. 24:1996;2849-2857.
39. Pikarsky E., Sharir H., Ben-Shushan E., Bergman Y. Retinoic acid represses Oct-3/4 gene expression through several retinoic acid-responsive elements located in the promoter-enhancer region. Molecular and Cellular Biology. 2:1994;1026-1038.
40. Georg B., Wulff B.S., Fahrenkrug J. Characterization of the effects of retinoic acid on vasoactive intestinal polypeptide gene expression in neuroblastoma cells. Endocrinology. 135:1994;1455-1463.
41. Waschek J.A., Lelievre V., Bravo D.T., Nguyen T., Muller J.M. Retinoic acid regulation of the VIP and PACAP autocrine ligand and receptor system in human neuroblastoma cell lines. Peptides. 18:1997;835-841.
42. Bassan M., Zamostiano R., Davidson A., Pinhasov A., Giladi E., Perl O., Bassan H., Blat G., Gibney G., Glazner G., Brenneman D.E., Gozes I. Complete sequence of a novel protein containing a femtomolar-activity-dependent neuroprotective peptide. Journal of Neurochemistry. 72:1999;1283-1293.
43. Zamostiano R., Pihasov A., Gelber E., Steingart R.A., Seroussi E., Giladi E., Bassan M., Wollman Y., Eyre H.J., Mulley J.C., Brenneman D.E., Gozes I. Cloning and Characterization of the human activity-dependent neuroprotective protein. Journal of Biological Chemistry. 272:2001;708-714.